Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:08 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 284 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Relapse-Remitting Multiple Sclerosis Clear all

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: Modified Atkins diet; Other
Lead sponsor: University of Virginia; Other
Eligibility: 12 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: BG00002 (natalizumab); Biological
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 53
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 46 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Not listed
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 38
States / cities: Homewood, Alabama • Tucson, Arizona • Colorado Springs, Colorado + 35 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Photobiomodulation Therapy, Placebo; Other
Lead sponsor: Marquette University; Other
Eligibility: 20 Years to 60 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: natalizumab, interferon beta 1-a, methylprednisolone, IV placebo, glatiramer acetate; Drug · Other
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 20
States / cities: Cullman, Alabama • San Francisco, California • Fort Collins, Colorado + 15 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Intermittent Hypoxia, Sham Hypoxia; Other
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: Midazolam, Caffeine, S-warfarin, Vitamin K, Omeprazole, Dextromethorphan, BIIB019 (Daclizumab); Drug · Other · Biological
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 7
States / cities: Centennial, Colorado • Washington D.C., District of Columbia • Lake Barrington, Illinois + 4 more

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: ALKS 8700, Dimethyl Fumarate; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 506 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 57
States / cities: Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more

Conditions: Relapsing Remitting Multiple Sclerosis, Clinically Isolated Syndrome
Interventions: Not listed
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 59 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Inosine; Drug
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Natalizumab; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 585 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 52
States / cities: Cullman, Alabama • Homewood, Alabama • Irvine, California + 45 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: BIIB017 (peginterferon beta-1a), Interferon beta type 1a; Drug
Lead sponsor: Biogen; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 3
States / cities: La Jolla, California • Chapel Hill, North Carolina • Norfolk, Virginia

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: Donepezil HCI (drug); Drug
Lead sponsor: Neurognostics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Clemastine, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: IMU-838 tablets, Placebo matching IMU-838 tablets; Drug
Lead sponsor: Immunic AG; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2033
U.S. locations: 2
States / cities: Altamonte Springs, Florida • Coral Springs, Florida

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: natalizumab, fingolimod; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 111 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 12
States / cities: Aurora, Colorado • Colorado Springs, Colorado • Port Charlotte, Florida + 9 more

Conditions: Relapsing-remitting Multiple Sclerosis, Clinically Isolated Syndrome
Interventions: Not listed
Lead sponsor: Providence Multiple Sclerosis Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Multiple Sclerosis
Interventions: BHT-3009-01; Biological
Lead sponsor: Bayhill Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 2
States / cities: Phoenix, Arizona • Los Angeles, California

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Betaferon/Betaseron; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 271 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 51
States / cities: Tucson, Arizona • Berkeley, California • Irvine, California + 46 more

Conditions: Multiple Sclerosis
Interventions: Rebif (IFN β-1a subcutaneous three times per week), Tecifdera (dimethyl fumarate); Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Brookline, Massachusetts

Conditions: Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis (RRMS)
Interventions: High Definition transcranial Direct Current Stimulation, Sham High Definition transcranial Direct Current Stimulation; Device
Lead sponsor: The University of Texas at Dallas; Other
Eligibility: 18 Years to 64 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Richardson, Texas

Conditions: Multiple Sclerosis
Interventions: Blood sample collection for coagulation profile; Diagnostic Test
Lead sponsor: St. Joseph's Hospital and Medical Center, Phoenix; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: Helminth ova; Biological
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 50 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
Interventions: Tovaxin Autologous T Cell Vaccine; Biological
Lead sponsor: Opexa Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 2
States / cities: Bellaire, Texas • Houston, Texas

Search by objective public record fields.

Utilization of the Ketogenic Diet in Patient With Relapsing Remitting MS

Natalizumab Re-Initiation of Dosing

Observational Registry of Acthar Gel for Participants With Multiple Sclerosis Relapse

Photobiomodulation Therapy in Persons With Multiple Sclerosis

Treatment Interruption of Natalizumab

Acute Intermittent Hypoxia in Persons With Multiple Sclerosis

An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis

A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2

Clinical Importance of Glucose Regulation in Relapsing MS

Treatment of Multiple Sclerosis Using Over the Counter Inosine

A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration

A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties

Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis

Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants

Safety/Effectiveness of Adding Monthly Dexamethasone to Weekly Avonex for MS

Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis

An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS

Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS

Non-invasive Brain Stimulation to Improve Memory in Multiple Sclerosis

VALIDATE: Factor VIII Trending for MS Relapse

Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis

Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis